Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Blood Products
Company developing synthetic blood substitute selects contract researcher
June 6th, 2005
Sanguine Corp. (SGNC), a bio-pharmaceutical company focused on developing an oxygen-carrying synthetic substitute for human red blood cells and other areas requiring oxygen profusion, has selected a contract researcher. Beckloff Associates Inc., a division of Cardinal Health, was chosen by Sanguine as its contract researcher to conduct U.S. Food and Drug Administration (FDA) testing programs for PHER-O2. The current endeavor includes developing testing projects for a select few indications using the oxygen-carrying attribute of PHER-O2. The analysis is expected to result in selecting a single indication and subsequent testing protocol. ...
Source: Biotech Business Week (2005-06-06)
|
